17767857. ONCOLYTIC VIRUS COMPRISING IMMUNOMODULATORY TRANSGENES AND USES THEREOF simplified abstract (Arizona Board of Regents on Behalf of Arizona State University)
Contents
- 1 ONCOLYTIC VIRUS COMPRISING IMMUNOMODULATORY TRANSGENES AND USES THEREOF
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 ONCOLYTIC VIRUS COMPRISING IMMUNOMODULATORY TRANSGENES AND USES THEREOF - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Unanswered Questions
- 1.11 Original Abstract Submitted
ONCOLYTIC VIRUS COMPRISING IMMUNOMODULATORY TRANSGENES AND USES THEREOF
Organization Name
Arizona Board of Regents on Behalf of Arizona State University
Inventor(s)
Douglas Grant Mcfadden of Tempe AZ (US)
Lino Torres-dominguez of Tempe AZ (US)
Mohammed Masmudur Rahman of Chandler AZ (US)
ONCOLYTIC VIRUS COMPRISING IMMUNOMODULATORY TRANSGENES AND USES THEREOF - A simplified explanation of the abstract
This abstract first appeared for US patent application 17767857 titled 'ONCOLYTIC VIRUS COMPRISING IMMUNOMODULATORY TRANSGENES AND USES THEREOF
Simplified Explanation
The patent application describes a Myxoma virus that expresses immunomodulatory transgenes for inhibiting and treating hematological cancer in a subject, as well as the use of leukocytes containing this virus for the same purpose.
- Myxoma virus engineered to express immunomodulatory transgenes
- Use of virus-infected leukocytes to treat hematological cancer
Potential Applications
The technology could be applied in the treatment of various types of hematological cancers, such as leukemia, lymphoma, and myeloma.
Problems Solved
This technology addresses the challenge of effectively targeting and treating hematological cancers, which can be difficult to treat with traditional methods.
Benefits
- Enhanced immune response against cancer cells - Targeted delivery of immunomodulatory agents to the tumor site - Potential for personalized treatment approaches
Potential Commercial Applications
"Enhancing Hematological Cancer Treatment with Myxoma Virus-Infected Leukocytes"
Possible Prior Art
There have been previous studies on using oncolytic viruses for cancer treatment, but the specific combination of Myxoma virus and immunomodulatory transgenes for hematological cancers may be novel.
Unanswered Questions
What are the potential side effects of using Myxoma virus-infected leukocytes for cancer treatment?
The article does not delve into the possible adverse effects that may arise from this treatment approach.
How does the immune system respond to the presence of Myxoma virus-infected leukocytes in the body?
The immune response to the engineered virus-infected leukocytes is not discussed in detail in the article.
Original Abstract Submitted
The disclosure provides Myxoma virus that expresses one or more immunomodulatory transgenes and its use in inhibiting and/or treating a hematological cancer in a subject. The disclosure also provides a leukocyte having a Myxoma virus that expresses one or more immunomodulatory transgenes and the use of the leukocyte for inhibiting and/or treating a hematological cancer in a subject.
